High level of agreement in a fixed vs. live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting

IntroductionAs recognition of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease becomes more widespread, the importance of appropriately ordering and interpreting diagnostic testing for this antibody increases. Several assays are commercially available for MOG testing, and based...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Tammy L. Smith, Thomas R. Haven, Lauren M. Zuromski, Kyphuong Luong, Stacey L. Clardy, Lisa K. Peterson
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2023-07-01
Σειρά:	Frontiers in Neurology
Θέματα:	myelin oligodendrocyte glycoprotein (MOG) cell-based assay (CBA) MOG testing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) demyelinating disease fixed CBA
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1192644/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!